RxDoctor Payments Data

David Bouska, MD

Family Medicine · Greensboro, NCNPI 1962446914

Payments from drug & device makers

$1,378in general payments, 2019–2025

Across 32 payments — averaging $43.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$353
  • AbbVie$292
  • Lilly USA, LLC$251
  • Exact Sciences$185
  • Antares Pharma, Inc.$55
  • Merck$42
  • plus $199 from 8 others

What the payments were for

  • Food & beverage$1,378100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,378 in reported general payments places this provider in the 70th percentile of 3,444 family medicine providers in North Carolina.

See all family medicine providers in North Carolina

Medicare billing

Part B allowed, 2024
$78,366
Medicare patients
162
Services billed
1,709

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide150$173,993
OzempicSemaglutide74$87,872
JardianceEmpagliflozin77$51,253
JanuviaSitagliptin Phosphate71$49,218
XareltoRivaroxaban46$45,291
EliquisApixaban64$45,168
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog21$26,044
MounjaroTirzepatide19$24,214
GlyxambiEmpagliflozin/Linagliptin20$18,825
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr37$17,593
JanumetSitagliptin Phos/Metformin Hcl15$13,766
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog21$13,523
FarxigaDapagliflozin Propanediol16$8,185
SymbicortBudesonide/Formoterol Fumarate27$6,219
GemtesaVibegron12$6,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$251$198,207169 claims
Novo NordiskOzempic$14$87,87274 claims
MerckJanuvia, Janumet$42$62,98386 claims
PfizerEliquis, Premarin$17$47,66976 claims
AstraZenecaFarxiga, Symbicort$353$14,40443 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,444 family medicine providers in North Carolina.

Other family medicine in Greensboro

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →